Related Experiment Video

Updated: Mar 17, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

895

Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma

Eric W Prince1, Ilango Balakrishnan1, Monil Shah2

  • 1Department of Pediatrics and Section of Pediatric Hematology/Oncology/BMT, Children's Hospital Colorado and University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, United States.

Oncotarget
|July 25, 2016
PubMed

Insights

Checkpoint kinase 1 (CHK1) inhibition shows promise for treating medulloblastoma, particularly Group 3. Combining CHK1 inhibitors with cisplatin offers a synergistic therapeutic strategy for this pediatric cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Checkpoint kinase 1 (CHK1) is crucial for cell cycle regulation and DNA Damage Response (DDR).
  • CHK1 is highly expressed in medulloblastoma, with elevated levels indicating poor prognosis in Group 3.
  • The role of CHK1 in medulloblastoma-associated DDR remains largely unexplored.

Purpose of the Study:

  • To investigate the role of CHK1 in medulloblastoma.
  • To evaluate the efficacy of CHK1 inhibition as a therapeutic strategy for medulloblastoma.
  • To explore the synergistic effects of CHK1 inhibition and cisplatin in medulloblastoma treatment.

Main Methods:

  • Utilized small-molecule CHK1 inhibitors (AZD7762, PF477736) and genetic knockdown (siRNA).
  • Assessed effects on cell growth, DNA damage, apoptosis, and protein expression.
  • Investigated combination therapy with cisplatin in medulloblastoma cell lines.

Main Results:

  • CHK1 inhibition decreased medulloblastoma cell growth, increased DNA damage, and induced apoptosis.
  • AZD7762 demonstrated synergy with cisplatin in reducing medulloblastoma cell proliferation.
  • Modulation of CHK1 pathway proteins suggests a feedback loop in CHK1 activation.

Conclusions:

  • Small-molecule CHK1 inhibition is a viable therapeutic strategy for medulloblastoma.
  • Combination therapy with CHK1 inhibitors and cisplatin shows significant therapeutic advantage, especially for Group 3 medulloblastoma.
  • This combined approach warrants further clinical investigation for medulloblastoma treatment.
Keywords:
CHK1Mycmedulloblastoma

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K